Long-term follow-up on tocilizumab treatment of AA amyloidosis secondary to polyarteritis nodosa

Amyloid. 2016 Dec;23(4):260-261. doi: 10.1080/13506129.2016.1232648. Epub 2016 Oct 28.

Authors

Jaka Ostrovršnik¹, Alojzija Hočevar¹, Boris Lestan¹, Snežna Sodin Šemrl^{1

2}, Katja Lakota¹, Matija Tomšič^{1

3}

Affiliations

¹ a Department of Rheumatology , University Medical Centre Ljubljana , Ljubljana , Slovenia.
² b Faculty of Mathematics, Natural Sciences and Information Technologies, University of Primorska , Koper , Slovenia , and.
³ c Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia.

PMID: 27791393
DOI: 10.1080/13506129.2016.1232648

No abstract available

Keywords: AA amyloidosis; Polyarteritis nodosa; serum amyloid A; tocilizumab; vasculitis.

Publication types

Case Reports

MeSH terms

Amyloidosis / complications
Amyloidosis / drug therapy*
Amyloidosis / metabolism
Amyloidosis / pathology
Antibodies, Monoclonal, Humanized / administration & dosage*
Antibodies, Monoclonal, Humanized / adverse effects
Anticholesteremic Agents / therapeutic use
Heart Function Tests
Humans
Hyperlipidemias / chemically induced
Hyperlipidemias / drug therapy
Hyperlipidemias / pathology
Polyarteritis Nodosa / complications
Polyarteritis Nodosa / drug therapy*
Polyarteritis Nodosa / metabolism
Polyarteritis Nodosa / pathology
Rosuvastatin Calcium / therapeutic use
Serum Amyloid A Protein / antagonists & inhibitors*
Serum Amyloid A Protein / metabolism
Time Factors
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Anticholesteremic Agents
Serum Amyloid A Protein
Rosuvastatin Calcium
tocilizumab